Hong Zhu

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 10

Top Topics

Epithelial Mesenchymal Transition

Molecular Dynamics Simulations

Top Venues

Journal of oncology

Journal of clinical medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Ying Miao, Tingting Zhang, Mingcheng Guan, Qian Zhao, Renxia Zhang, Xuyi Liu, Tianrun Ma, Tengfei Ren, Zhijin Zheng, Wei He, Wanying Tian, Qun Cui, Xingyu Zhai, Yibo Zuo, Hong Zhu, Hui Zheng, Yukang Yuan
DDX4 enhances antiviral activity of type I interferon by disrupting interaction of USP7/SOCS1 and promoting degradation of SOCS1. mBio 15 (3) (2024)
Ying Miao, Tingting Zhang, Mingcheng Guan, Qian Zhao, Renxia Zhang, Xuyi Liu, Tianrun Ma, Tengfei Ren, Zhijin Zheng, Wei He, Wanying Tian, Qun Cui, Xingyu Zhai, Yibo Zuo, Hong Zhu, Hui Zheng, Yukang Yuan
DDX4 enhances antiviral activity of type I interferon by disrupting interaction of USP7/SOCS1 and promoting degradation of SOCS1. mBio 15 (3) (2024)
Ying Miao, Tingting Zhang, Mingcheng Guan, Qian Zhao, Renxia Zhang, Xuyi Liu, Tianrun Ma, Tengfei Ren, Zhijin Zheng, Wei He, Wanying Tian, Qun Cui, Xingyu Zhai, Yibo Zuo, Hong Zhu, Hui Zheng, Yukang Yuan
DDX4 enhances antiviral activity of type I interferon by disrupting interaction of USP7/SOCS1 and promoting degradation of SOCS1. mBio (2024)
Ying Miao, Tingting Zhang, Mingcheng Guan, Qian Zhao, Renxia Zhang, Xuyi Liu, Tianrun Ma, Tengfei Ren, Zhijin Zheng, Wei He, Wanying Tian, Qun Cui, Xingyu Zhai, Yibo Zuo, Hong Zhu, Hui Zheng, Yukang Yuan
DDX4 enhances antiviral activity of type I interferon by disrupting interaction of USP7/SOCS1 and promoting degradation of SOCS1. mBio 15 (3) (2024)
Ming-Cheng Guan, Qian Ding, Jing Ning, Hong Zhu
Metformin as a booster or obstacle of immunotherapy in patients with non-small cell lung cancer and diabetes mellitus. Cancer (2023)
Wei Ouyang, Ming-Da Wang, Wan-Yin Wang, Chao Li, Lan-Qing Yao, Hong Zhu, Feng Shen
Hydroxymethylation and Epigenetic Drugs: New Insights into the Diagnosis and Treatment in Epigenetics of Hepatocellular Carcinoma. Journal of oncology 2023 (2023)
Wei Ouyang, Ming-Da Wang, Wan-Yin Wang, Chao Li, Lan-Qing Yao, Hong Zhu, Feng Shen
Hydroxymethylation and Epigenetic Drugs: New Insights into the Diagnosis and Treatment in Epigenetics of Hepatocellular Carcinoma. Journal of oncology 2023 (2023)
Siyu Liu, Liyang Sun, Lanqing Yao, Hong Zhu, Yongkang Diao, Mingda Wang, Hao Xing, Wan Yee Lau, Mingcheng Guan, Timothy M Pawlik, Feng Shen, Min Xu, Xiangmin Tong, Tian Yang
Diagnostic Performance of AFP, AFP-L3, or PIVKA-II for Hepatitis C Virus-Associated Hepatocellular Carcinoma: A Multicenter Analysis. Journal of clinical medicine 11 (17) (2022)
Ming-Da Wang, Nan-Ya Wang, Hui-Lu Zhang, Li-Yang Sun, Qiu-Ran Xu, Lei Liang, Chao Li, Dong-Sheng Huang, Hong Zhu, Tian Yang
Fatty acid transport protein-5 (FATP5) deficiency enhances hepatocellular carcinoma progression and metastasis by reprogramming cellular energy metabolism and regulating the AMPK-mTOR signaling pathway. Oncogenesis 10 (11) (2021)
Quan Lin, Haoran Zhang, Huaxin Ding, Jun Qian, Analyn Lizaso, Jing Lin, Han Han-Zhang, Jianxing Xiang, Yuping Li, Hong Zhu
The association between BRAF mutation class and clinical features in BRAF-mutant Chinese non-small cell lung cancer patients. Journal of translational medicine 17 (1) (2019)